102 related articles for article (PubMed ID: 16334130)
1. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Picus J; Halabi S; Kelly WK; Vogelzang NJ; Whang YE; Kaplan EB; Stadler WM; Small EJ;
Cancer; 2011 Feb; 117(3):526-33. PubMed ID: 20862750
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Gross M; Higano C; Pantuck A; Castellanos O; Green E; Nguyen K; Agus DB
BMC Cancer; 2007 Jul; 7():142. PubMed ID: 17662137
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Rathkopf D; Carducci MA; Morris MJ; Slovin SF; Eisenberger MA; Pili R; Denmeade SR; Kelsen M; Curley T; Halter M; Collins C; Fleisher M; Heller G; Baker SD; Scher HI
J Clin Oncol; 2008 Jun; 26(18):2959-65. PubMed ID: 18565882
[TBL] [Abstract][Full Text] [Related]
4. New paradigms for advanced prostate cancer.
Petrylak DP
Rev Urol; 2007; 9 Suppl 2(Suppl 2):S3-S12. PubMed ID: 17554403
[TBL] [Abstract][Full Text] [Related]
5. The treatment of hormone-refractory prostate cancer: docetaxel and beyond.
Petrylak DP
Rev Urol; 2006; 8 Suppl 2(Suppl 2):S48-55. PubMed ID: 17021642
[TBL] [Abstract][Full Text] [Related]
6. Innovative therapies for prostate cancer treatment.
Syed S; Tolcher A
Rev Urol; 2003; 5 Suppl 3(Suppl 3):S78-84. PubMed ID: 16985955
[TBL] [Abstract][Full Text] [Related]
7. Oncoxin-Viusid
Fundora Ramos MI; Maden LB; Casanova FO; Cruz FH; Reyes CS; Gato AH; Lyncon IB; González EV; Morales KP; Lence JJ; Sanz E
Mol Clin Oncol; 2021 Jan; 14(1):5. PubMed ID: 33235733
[TBL] [Abstract][Full Text] [Related]
8. Update in palliative management of hormone refractory cancer of prostate.
Singh P; Srivastava A
Indian J Urol; 2007 Jan; 23(1):43-50. PubMed ID: 19675762
[TBL] [Abstract][Full Text] [Related]
9. Undifferentiated prostate cancer treated with docetaxel.
Kobayashi M; Yokoyama M; Inoue M; Fujii Y
IJU Case Rep; 2020 Jul; 3(4):125-127. PubMed ID: 33392469
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.
Roudsari NM; Lashgari NA; Momtaz S; Abaft S; Jamali F; Safaiepour P; Narimisa K; Jackson G; Bishayee A; Rezaei N; Abdolghaffari AH; Bishayee A
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452154
[TBL] [Abstract][Full Text] [Related]
11. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.
Roy M; Kung HJ; Ghosh PM
Am J Cancer Res; 2011; 1(4):542-61. PubMed ID: 21984972
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.
Mooso B; Madhav A; Johnson S; Roy M; Moore ME; Moy C; Loredo GA; Mehta RG; Vaughan AT; Ghosh PM
Genes Cancer; 2010 Nov; 1(9):927-940. PubMed ID: 21552398
[TBL] [Abstract][Full Text] [Related]
13. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
14. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.
Gignac GA; Morris MJ; Heller G; Schwartz LH; Scher HI
Cancer; 2008 Sep; 113(5):966-74. PubMed ID: 18661513
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
19. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
